Alex F Herrera
City of Hope Medical Center
9
9
1
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+22 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Thomas E. Witzig, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Ajay Gopal
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Shaji Kumar
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Ryotaro Nakamura
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Kevin C Conlon, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
George Wilding
University of Wisconsin, Madison
Shared therapeutic areas:
Worked with same sponsors:
Ajay Gopal
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
All 9 trials loaded